Vaginal and Postpregnancy Inflamations, Risks of their Treatment for Fetus
Authors:
E. Maňáková; L. Hubičková Heringová
Authors‘ workplace:
Česká teratologická informační služba 3. LF UK, Praha
Published in:
Ceska Gynekol 2008; 73(5): 294-297
Category:
Original Article
Overview
Objective:
Paper describes risks of gynaecological inflamations and their treatment for the successful course of pregnancy.
Design:
Review.
Setting:
Czech Teratology Information Service, 3. LF UK, Praha.
Subject and methods:
The article refers the most common types of vaginal inflamation and gives recommendation for the appropriate treatment that is safe for embryo or fetus according to advice of Teratology Information Service.
Conclusion:
Vaginal inflamation during pregnancy represents risks of abortion, miscarriage or prematurity. For the treatment, we have to take in consideration the age of pregnancy and we should use the drugs, that are safe during this period. It is necessary always to compare risks resulting from disorder and from drugs used.
Key words:
bacterial vaginitis, candidosis, therapy during pregnancy.
Sources
1. Acs, N., Bánhidy, F., Puhó, E, et al. Teratogenic effects of vaginal boric acid during pregnancy. Int J Gyneacol Obstet 2006, 93, 1, p. 55-56.
2. Al-Sabbagh, A., Moss, S., Subhedar, N. Neonatal necrotising enterocolitis and perinatal exposure to co-amoxiclav. Arch Dis Child Fetal Neonatal Ed. 2004, 89, 2, p. 187.
3. Carter, TC., Druschel, CM., Romitti, PA., et al. Antifungal drugs and the risk of selected birth defects. Am J Obstet Gynecol, 2008, 198, 2, p. 191.e1-7.
4. Eschenbach, DA. Bacterial vaginosis: Resistence, recurrence and/or reinfection? Clin Infect Dis, 2007, 44, p. 220-221.
5. Fail, PA., Chapin, RE., Price, CJ., et al. General, reproductive, developmental, and endocrine toxicity of boronated compounds. Reprod Toxicol.1998, 2. 1, p. l-18.
6. Garland, SM., O’Reilly, MA. The risks and benefits of antimicrobial therapy in pregnacy. Drug Safety. 1995, 13, p. 188-205.
7. Gibbs, RS. Asymptomatic bacterial vaginosis: is it time to treat? Am J Obstet Gynecol, 2007, 196, 6, p. 495-496.
8. Gilstrap, LC., Faro, S. Infection in pregnancy. 2. ed. New York, Toronto: Wiley-Liss, 1997. p. 1-7.
9. Goldenberg, RL., Andrews, WW., Goepfert, AR., et al. The Alabama preterm birth study: Umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants. Am J Obstet Gynecol, 2008, 198, 43, p. e1- e5.
10. Kragie, L., Turner, SD., Patten, CJ., et al. Assessing pregnancy risks of azole antifungals using a high throughput aromatase inhibition assay. Endocr Res, 2002, 28, 3, p. 129-140.
11. Kenyon, SL., Taylor, DJ., Tarnow-Mordi, W. (ORACLE Collaborative Group). Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. Lancet, 2001, 357, p. 989–994.
12. Kenyon, SL., Taylor, DJ., Tarnow-Mordi, W. (ORACLE Collaborative Group). Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. Lancet, 2001, 357, p. 979–988.
13. Larsen, JW., Sever, JL. Group B streptococcus and pregnancy: a review. Am J Obstet Gynecol, 2008, 198, 4, p. 440–448.
14. Larsson, P., Fahraeus, L., Carlsson, B., et al. Late miscarriage and preterm birth after treatment with clindamycin: a randomised consent design study according to Zelen. BJOG, 2006, 113, p. 629-637.
15. McGregor, JA., French, JI., Jones, W., et al. Association of cervicovaginal infections with increased vaginal fluid phospholipase A2 activity. Am J Obstet Gynecol, 1992, 167, 6, p. 1588-1594.
16. Medling, W., Seebacher, C. Leitlinie zur Vulvovaginalkandidose. Stand 6. 11. 2002 Arbeitsgemeinschaft für Infektionen und Infektionsimmunologie (AGII) der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe und Deutschsprachige Mykologische Gesellschaft e. V. J Dtsch Dermatol Ges, 2004, 2, 2, S. 149–152.
17. Nygren, P., Fu, R., Freeman, M., et al. Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. Preventive Services Task Force. Ann Intern Med, 2008, 148, p. 220-233.
18. Pereira, L., Culhane, J., McCollum, K., et al. Variation in microbiologic profiles among pregnant women with bacterial vaginosis. Am J of Obstet Gynecol, 2005, 193, p. 746–751.
19. Schaefer, C., Peters, P., Miller, RK. Drugs during pregnancy and lactation. 2. ed. Amsterdam, Boston, Heidelberg: Elsevier 2007.
20. Schaller, M., Korting, HC., Borelli, C., et al. Candida albicans-secreted aspartic proteinases modify the epithelial cytokine response in an in vitro model of vaginal candidiasis. Infect Immun, 2005, 73, 5, p. 2758-2765.
21. Schwebke, JR., Desmond, RA. A randomised trial of length of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis, 2006, 43, p. 213-219.
22. Senn, L., Hammerschlag, MR., Greub, G. Therapeutic approaches to Chlamydia infections. Expert Opin Pharmacother, 2005, 6, 13, p. 2281-2290.
23. Simcox, R., Sin, WA., Seed, P., et al. Prophylaxic antibiotics for the prevention of preterm birth in women at risk: A meta-analysis. Aust N Z J Obstet Gynaecol, 2007, 47, 5, p. 368-377.
24. Svare, J., Schmidt, H., Hansen, B., et al. Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections. BJOG, 2006, 113, p. 1419–1425.
25. Swidsinski, A., Mendling, W., Loening-Baucke, V., et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standart therapy with oral metronidazole. Am J Obstet Gynecol, 2008, 198, 97, p. e1-e6.
26. Ugwumadu, A., Reid, F., Hay, P., et al. Oral clindamycin and histologic chorioamnionitis in women with abnormal vaginal. Obstet Gynecol, 2006, 107, 4, p. 863-868.
27. Verstraelen, H., Verhelst, R., Roelens K., et al. Modified classification of Gram-stained vaginal smears to predict spontaneous preterm birth: a prospective cohort study. Am J Obstet Gynecol, 2007, 196, p. 528, e.1-e6.
28. Vogel, I., Thorsen, P., Jeune B., et al. Acquisition and elimination of bacterial vaginosis during pregnancy: A danish population based study. Infect Dis Obstet Gynecol, 2006: ID 94646, p. 1-6.
29. Wéry, N., Narotsky, MG., Pacico, N., et al. Defects in cervical vertebrae in boric acid-exposed rat embryos are associated with anterior shifts of hox gene expression domains. Birth Defects Research (Part A), 2003, 67, p. 59-67.
30. Yoon, BH., Romero, R., Moon, JB., et al. The frequency and clinical significance of intra-amniotic inflammation in patients with a positive cervical fetal fibronectin. Am J Obstet Gynecol, 2001, 185, p. 1137–1142.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Czech Gynaecology
2008 Issue 5
Most read in this issue
- Long-term Low Molecular Weight Heparin Protection during Pregnancy for the Recurrent Fetal Loss
- Myoms, Fertility and Pregnancy
- Caesarean Section – Indication or Choice?
- Vaginal and Postpregnancy Inflamations, Risks of their Treatment for Fetus